The TRIOMPHE IDE study will enrol 100 particpants at up to 30 sites. Credit: Robina Weermeijer / Unsplash.

Israeli company Endospan has announced the first implant of its NEXUS Aortic Arch Stent Graft System on a patient with a thoracic aortic aneurysm in the TRIOMPHE Study being carried out in Sentara Norfolk General Hospital, Virginia, US.

It is estimated that more than 120,000 patients suffer thoracic aortic arch disease in the US and Europe yearly, but only 25% of them are diagnosed or treated.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Even though minimally invasive, endovascular repair is the standard of care for abdominal aortic aneurysm (AAA), aortic arch disease patients having aneurysms or dissections have no choice other than undergoing invasive open-chest surgery.

The CE Mark-approved system is designed for treating patients diagnosed with a dilative lesion in or near the aortic arch in a minimally invasive manner.

The company noted that minimally invasive repair reduces the need for extracorporal circulation and chances of hypothermia, resulting in a minimal procedure and hospitalisation period.

The multi-arm, multi-centre, non-randomised, prospective clinical study will analyse the safety and effectiveness of NEXUS in treating thoracic aortic lesions, involving the aortic arch.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company said it will enrol 100 participants at up to 30 sites.

Endospan CEO Kevin Mayberry said: “With the first patient enrolled in the TRIOMPHE IDE study, Endospan marks the next crucial milestone towards US approval for the NEXUS Aortic Arch Repair Stent Graft System.

“The NEXUS is specifically engineered for total endovascular arch repair to address the specific challenges of the aortic arch anatomy.

“With this study, we aim to prove the NEXUS will provide surgeons a straightforward, minimally invasive solution for aortic arch repair that allows for procedural consistency with reliable patient outcomes.”

Last August, Endospan received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to start the TRIOMPHE study on the NEXUS Aortic Arch Stent Graft System.